Hormone therapy: Maximizing the benefits

Gynecological Endocrinology

Volumn 22, Issue 3, 2006, Pages 160-162

  Heikkinen, Jorma ^a  

^a OULU DEACONESS INSTITUTE   (Finland)

Author keywords

Climacteric symptoms; Hormone therapy; Menopause; Osteoporosis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DRUG INDICATION; FEMALE; FRACTURE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; VAGINA ATROPHY; WELLBEING;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS; RISK ASSESSMENT; RISK FACTORS;

EID: 33745728350     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590600629183     Document Type: Article

References (23)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
2. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
3. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004;291:1701-1712.
4. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7:1-6.
5. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002;16:795-806.
6. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002;50:1644-1650.
7. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767.
8. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A; Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-539.
9. Stevenson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005;51:113-126.
10. Banks E, Beral V, Reeves G, Balkwill A, Barnes I, for the Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. J Am Med Assoc 2004;291:2212-2220.
11. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-735.
12. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, Lacroix AZ, LeBoff M, Lewis CE, McGowan CE, Neuner J, et al.; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J Am Med Assoc 2003;290:1729-1738.
13. Kyllonen ES, Heikkinen JE, Vaananen HK, Kurttila-Matero E, Wilen-Rosenqvist G, Lankinen KS, Vanharanta JH. Influence of estrogen-progestin replacement therapy and exercise on lumbar spine mobility and low back symptoms in a healthy early postmenopausal female population: a 2-year randomized controlled trial. Eur Spine J 1998;7:381-386.
14. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 2002;287:2668-2676.
15. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int 2000;11:929-937.
16. Mattsson L-Å, Skouby SO, Heikkinen J, Vaheri R, Mäenpää J, Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional dose regimen. Climacteric 2004;7:59-69.
17. Vaheri R, Kainulainen P, Timonen U, Heikkinen J. Bone mineral density in postmenopausal women during and after long-term use of standard and low-dose estrogen-progestin therapies. Program of the 11th World Congress on the Menopause, Buenos Aires, Argentina, 2005.
18. Komulainen M, Kroger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarikoski S. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos Int 2000;11:211-218.
19. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551.
20. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women. Arch Intern Med 2004;164:4782-4784.
21. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
22. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983.
23. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004;10:95-102.